학술논문
A randomized, double-blind, placebo-controlled 16 week study of the H3 receptor antagonist GSK239512 in subjects with mild-to-moderate Alzheimer's disease (AD)
Document Type
Abstract
Source
In Alzheimer's & Dementia: The Journal of the Alzheimer's Association July 2011 7(4) Supplement:e58-e59
Subject
Language
ISSN
1552-5260